证券代码：688366 证券简称：昊海生科 公告编号：2025-038 上海昊海生物科技股份有限公司 自愿披露关于签订《终止合作协议》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、前次交易的基本情况 2021 年 3 月 19 日，上海昊海生物科技股份有限公司（"公司"）全资子公 司昊海生物科技控股有限公司（"昊海控股"）与亨泰光学股份有限公司（"亨 泰光学"）、上海亨泰视觉科技有限公司（"亨泰视觉"）签署《独家经销合同》 《技术授权合约书》（以下合称"独家经销协议"），约定亨泰光学授予亨泰视 觉高端角膜塑形用硬性透气接触镜产品（OK 镜）"迈儿康 myOK"于中国大陆 地区、期限为 10 年（截至 2030 年 12 月 31 日）的独家经销权，昊海控股作为采 购平台；并持续授予亨泰视觉儿童近视管理及控制的光学镜片"贝视得"于中国 大陆地区的独家经销权。同时，公司全资子公司上海昊海医药科技发展有限公司 （以下简称"昊海发展"）与亨泰视觉及其股东签订《投资协议》，通过股权转 让以及增资的方式以人民币 2,50 ...

昊海生科公告，因Carl Zeiss Vision International GmbH拟通过股份转换形式收购亨泰光学100%股份，亨 泰光学控制权变更，导致原合作协议重大变化。经友好协商，昊海控股与亨泰光学主要股东签署《终止 合作协议》，亨泰视觉少数股东金亨泰（厦门）贸易有限公司将其持有的亨泰视觉45%股权转让给昊海 发展。此外，亨泰光学主要股东及利害关系人向昊海控股支付终止合作补助金人民币8000万元。该事项 无需提交董事会、股东会审议，公司与协议相对方不存在关联关系。 ...

Core Viewpoint - The company, Haohai Biological Technology Co., Ltd., has a current stock price of 56.75 yuan, with a rolling PE ratio of 31.94, marking a new low in 94 days, and a total market capitalization of 13.199 billion yuan [1] Company Summary - Haohai Biological specializes in the research, production, and sales of medical devices and pharmaceuticals, with key products including ophthalmic viscoelastic devices, artificial lenses, optical materials, hyaluronic acid, and medical chitosan [1] - The latest quarterly report for Q1 2025 shows the company achieved a revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit of 90.312 million yuan, down 7.41%, with a gross profit margin of 69.52% [1] Industry Summary - The average PE ratio for the medical device industry is 59.49, with a median of 40.19, positioning Haohai Biological at 61st place within the industry [2] - The company’s PE ratio is significantly lower than the industry average, indicating potential undervaluation compared to peers [2]

Group 1 - The latest stock price of Haohai Biological Technology is 55.18 yuan, an increase of 1.01% compared to the previous trading day [1] - The trading volume on the same day was 11,236 lots, with a total transaction amount of 0.62 billion yuan [1] - Haohai Biological Technology operates in the medical device industry, with its main business in pharmaceutical manufacturing, accounting for 99.83% of its operations [1] Group 2 - As of August 14, the company has completed its current share repurchase plan, having repurchased approximately 1.83 million A-shares, which represents 0.79% of the total share capital [1] - The average repurchase price was 56.7 yuan per share, with a total expenditure of approximately 1.04 billion yuan [1] - On August 15, the net outflow of main funds was 4.30 million yuan, with a cumulative net outflow of 4.95 million yuan over the past five days [1]

Core Viewpoint - The company has successfully completed its second phase of A-share repurchase, acquiring a total of 1,832,421 shares, which represents 0.79% of its total share capital, with a total expenditure of approximately 103.91 million yuan [1][3][4]. Summary by Sections Repurchase Plan and Approval - The repurchase plan was first disclosed on August 17, 2024, with a total expected repurchase amount between 100 million yuan and 200 million yuan, and a maximum repurchase price of 89.71 yuan per share [1]. - The board approved the repurchase on August 16, 2024, and the implementation period is from August 16, 2024, to August 15, 2025 [1]. Adjustments to Repurchase Price - Following the implementation of the 2024 semi-annual equity distribution, the maximum repurchase price was adjusted from 89.71 yuan to 89.31 yuan per share [2]. - After the 2024 annual equity distribution, the maximum repurchase price was further adjusted to 88.72 yuan per share [2]. Implementation Status - The company initiated the repurchase on November 26, 2024, and completed the repurchase by August 14, 2025, acquiring a total of 1,832,421 shares at an average price of 56.70 yuan per share [3][4]. - The total funds used for the repurchase amounted to approximately 103.91 million yuan, excluding taxes and transaction fees [3]. Share Distribution Changes - Prior to the repurchase, the total share count was 235,489,895 shares, which decreased to 232,581,095 shares post-repurchase [4][5]. - The repurchased shares will be used for employee stock ownership plans or equity incentives and will not enjoy voting rights or profit distribution during the holding period [6]. Future Plans for Repurchased Shares - The repurchased shares are intended to be transferred within three years; if not transferred, they will be canceled and the registered capital will be reduced accordingly [6].

昊海生物科技(06826)发布公告，关于第二期A股股份回购实施结果，截至2025年8月14日，公司已完成 本期回购。公司通过上海证券交易所系统以集中竞价交易方式已累计回购A股股份183.24万股，占公司 总股本比例为0.79%，回购成交的最高价为63.58元/股，最低价为49.25元/股，回购均价为56.70元/股， 支付的资金总额为人民币1.039亿元(不含印花税、交易佣金等费用)。 ...

智通财经APP讯，昊海生物科技(06826)发布公告，关于第二期A股股份回购实施结果，截至2025年8月 14日，公司已完成本期回购。公司通过上海证券交易所系统以集中竞价交易方式已累计回购A股股份 183.24万股，占公司总股本比例为0.79%，回购成交的最高价为63.58元/股，最低价为49.25元/股，回购 均价为56.70元/股，支付的资金总额为人民币1.039亿元(不含印花税、交易佣金等费用)。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司關 於第二期A股股份回購實施結果公告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年8月15日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生；及本公司 之獨立非執行董事為沈紅波先生、姜志宏先生、蘇治先生及楊玉社先生。 一、 回购审批情况和回购方案内容 上海昊海生物科技股份有限公司 ...

Group 1 - The core business of Haohai Biological Technology is primarily in the pharmaceutical manufacturing sector, accounting for 99.83% of its revenue, while other businesses contribute only 0.17% [1] Group 2 - As of August 15, 2025, Haohai Biological Technology has completed its share repurchase program, acquiring approximately 1.83 million A-shares, which represents 0.79% of the total share capital of about 233 million shares [3] - The highest price for the repurchased shares was 63.58 CNY per share, the lowest was 49.25 CNY per share, and the average repurchase price was 56.7 CNY per share, with a total expenditure of approximately 104 million CNY [3]

证券代码：688366 证券简称：昊海生科 公告编号：2025-037 上海昊海生物科技股份有限公司 关于第二期 A 股股份回购实施结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/8/17 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2024 8 8 | 16 | 日~2025 | 年 | 月 | 日 15 | | 预计回购金额 | 10,000.00万元~20,000.00万元 | | | | | | | 回购价格上限 | 88.72元/股（调整前为 89.71 | | | | | 元/股） | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 实际回购股数 | 1,832,421股 | | | | | ...